By: IPP Bureau
Last updated : July 06, 2025 5:47 pm
Suraksha Diagnostic Limited (Suraksha Daignostic), one of the leading diagnostics chains in Eastern India has launched one of the largest and a state-of-the-art genomics labs in Eastern India. The launch was graced by Prof. Sukumar Mukherjee, a distinguished rheumatologist with more than 35 years of extensive experience in the field and a mentor at Suraksha Diagnostic.
The global genetic testing market is valued at USD 38.77 billion (2024) and is projected to reach US$ 186.64 billion by the year 2035 (CAGR: 22.5%). In a landmark move, Suraksha Diagnostic has invested ₹22 crores in establishing its Genomics Lab. An additional Rs. 46 crore investment is planned over the next 24 months to establish one of Asia's most advanced Genomics Laboratories. This initiative is a significant leap forward for West Bengal, Eastern & North-Eastern India, and India's future in precision diagnostics.
This Lab is equipped with Cytogenetics, Microarray Technology, Sanger Sequencing, Multiple Next-Generation Sequencers (NGS). Together, these technologies enable the full spectrum of advanced genetic testing, offering predictive, preventive, and personalized care.
Speaking on the launch of the genomics lab, Dr. Somnath Chatterjee, Chairman & Joint Managing Director, Suraksha Diagnostic, said: "A huge transformation is sweeping across medicine today. At the heart of this revolution lies Genomics - unlocking the secrets of the Human Genome, enabling early diagnosis, predictive analytics, and personalized treatments. From Fetal Medicine to Oncology and Rare Diseases, genomic science is rewriting the future of healthcare. Suraksha Diagnostic is proud to be at the forefront of this revolution."
Ritu Mittal, Joint Managing Director & CEO, Suraksha Diagnostic, also emphasized the lab's role in making genomic diagnostics a critical part of healthcare decision- making in Eastern India and shared: "We provide end-to-end solution for prenatal genetics, offering comprehensive testing facilities. We aim to be a premium, aspirational choice for clinicians and families seeking the highest standards in fetal, reproductive, paediatric and onco-genetics without the need to send samples out of the region or compromise on quality."